Table 2 Association of PPARD and PPARG polymorphisms with glioma risk.

From: The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis

Gene	SNP	Chr: position	HaploReg v4.1	Group	Genotype			Allele frequency		Model	OR(95%CI)	P	FDR-P
Gene	SNP	Chr: position	HaploReg v4.1	Group	AA	AB	BB	MAF (A)	HWE- P	Model	OR(95%CI)	P	FDR-P
PPARD	rs2016520	6: 35378778	SiPhy cons, Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, GRASP QTL hits, Selected eQTL	case	31	217	317	0.247		Allele	0.82(0.68–0.99)	0.041	0.214
				control	37	217	255	0.286	0.385	Co-dominant	0.67(0.40–1.11)	0.123	0.323
											0.80(0.62–1.03)	0.085	0.275
										Dominant	0.78(0.62–1.00)	0.047	0.214
										Recessive	0.74(0.45–1.21)	0.231	0.404
										Additive	0.81(0.67–0.99)	0.037	0.214
PPARD	rs67056409	6: 35383699	Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, Selected eQTL	case	32	226	310	0.255		Allele	0.82(0.68–1.00)	0.046	0.214
				control	40	219	250	0.294	0.455	Co-dominant	0.64(0.39–1.06)	0.081	0.275
											0.83(0.65–1.07)	0.147	0.323
										Dominant	0.80(0.63–1.02)	0.072	0.275
										Recessive	0.70(0.43–1.13)	0.146	0.323
										Additive	0.82(0.67–0.99)	0.041	0.214
PPARD	rs1053049	6: 35395618	DNAse, Motifs changed, GRASP QTL hits, Selected eQTL	case	30	203	334	0.232		Allele	0.78(0.64–0.95)	0.012	0.214
				control	39	206	264	0.279	1.000	Co-dominant	0.60(0.37–1.00)	0.051	0.214
											0.78(0.60–1.00)	0.051	0.214
										Dominant	0.75(0.59–0.96)	0.020	0.214
										Recessive	0.67(0.41–1.10)	0.114	0.323
										Additive	0.78(0.64–0.95)	0.012	0.214
PPARD	rs2206030	6: 35404354	Enhancer histone marks, Motifs changed, NHGRI/EBI GWAS hits, Selected eQTL	case	126	291	151	0.478		Allele	1.08(0.91–1.28)	0.371	0.546
				control	106	255	148	0.459	0.929	Co-dominant	1.17(0.83–1.65)	0.382	0.546
											1.12(0.84–1.48)	0.436	0.573
										Dominant	1.13(0.87–1.48)	0.361	0.546
										Recessive	1.08(0.81–1.45)	0.587	0.685
										Additive	1.08(0.91–1.29)	0.365	0.546
PPARG	rs2920503	3: 12324230	Motifs changed	case	55	233	280	0.302		Allele	1.00(0.83–1.20)	0.985	0.986
				control	43	221	245	0.302	0.529	Co-dominant	1.12(0.72–1.73)	0.612	0.695
											0.92(0.72–1.19)	0.529	0.635
										Dominant	0.95(0.75–1.21)	0.702	0.776
										Recessive	1.16(0.76–1.77)	0.482	0.595
										Additive	1.00(0.83–1.20)	0.986	0.986
PPARG	rs4073770	3: 12368233	Enhancer histone marks, Motifs changed, Selected eQTL	case	60	265	243	0.339		Allele	0.99(0.83–1.19)	0.924	0.972
				control	69	209	231	0.341	0.061	Co-dominant	0.83(0.56–1.22)	0.339	0.546
											1.21(0.93–1.56)	0.152	0.323
										Dominant	1.11(0.87–1.41)	0.390	0.546
										Recessive	0.75(0.52–1.09)	0.132	0.323
										Additive	0.99(0.83–1.18)	0.925	0.971
PPARG	rs1151988	3: 12511512	Enhancer histone marks, Motifs changed, GRASP QTL hits, Selected eQTL	case	7	133	428	0.129		Allele	0.84(0.66–1.07)	0.162	0.324
				control	9	135	365	0.150	0.488	Co-dominant	0.66(0.24–1.80)	0.418	0.566
											0.84(0.64–1.11)	0.217	0.396
										Dominant	0.83(0.63–1.09)	0.175	0.334
										Recessive	0.69(0.26–1.87)	0.470	0.595
										Additive	0.83(0.65–1.07)	0.154	0.323

SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; FDR, false discovery rate.
Bold values indicate statistical significance (P < 0.05).

Back to article page

Table 2 Association of PPARD and PPARG polymorphisms with glioma risk.

Search

Quick links